Biotech Daily Home

Biotech Daily covers the major announcements from ASX-listed biotech companies as well as the major research institutes and developments in government policy.

Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotech sector.

The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter.

Subscriptions are $A940 a year (including GST in Australia) and a 10% discount is available for members of AusBiotech, the Bio-Melbourne Network and Life Sciences Queensland.

Subscribers include biotech directors and CEOs, major pharmaceutical companies, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.

The website is best viewed with the Firefox browser.

Download subscription form here



Latest News !

Dr Boreham's Crucible: Neuren

Biotech Daily Editorial: Welcome To 2017 

2016 - The Year In Review: Money, Malcolm & Medical Marijuana

10-Year BDI-40 Up 163%, ASX200 Up 3%, Big Caps Up 308%

Novartis Buys Spinifex For $916m

BRIL Group Senate Innovation Submission:
Set Aside 25% Of $20bn MRFF For Commercialization


February BDI-40 Down 2%, ASX200 Up 2%
Big Caps Up 5%, NBI Up 7%


Benitec Up 65%, Bionomics 19%; Compumedics Down 33%, Clinuvel 16%
Aviragen (Biota) almost gone, following Sunshine Heart


March 1, 2017
The Biotech Daily Top 40 Index (BDI-40) fell 1.9 percent in February, compared to the ASX200 up 1.6 percent and the Nasdaq Biotechnology Index (NBI) rising 6.8 percent.
The three Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) collectively climbed 4.9 percent in February and 15.0 percent for the year to February 28.
For the 12 months to February 28, 2017, the BDI-40 was up 1.0 percent, the ASX200 rose 17.0 percent and the NBI was up 16.8 percent.
Just 11 of the BDI-40 companies were up, with four up by more than 10 percent, while 25 fell, with seven down by more than 10 percent.
Yesterday’s unexpected Compumedics tumble on its first half results led the February falls, down 33.3 percent to a market capitalization of $78 million, followed by Clinuvel easing 16.4 percent to $321 million, Oncosil (14.9%), Viralytics (14.8%), Cyclopharm (12.3%), Uscom (10.7%) and Medical Developments (10.2%).
Benitec was February’s best, up 65.0 percent to $33 million on news that it can deliver BB-201 for age-related macular degeneration to the back of the eye, followed by Bionomics (18.9%),Universal Biosensors (15.3%) and Sirtex (10.8%).
Outside the BDI-40, Analytica, Dorsavi and Medlab Clinical have shown continuous improvement, but ITL Health Group has more than doubled in market capitalization in the past four months to $45 million and demonstrated continuous innovation and expansion. ITL will be promoted to the Second 20 from today, replacing Anteo Diagnostics.
On the Nasdaq, Israel’s Redhill was up 0.5 percent to $214 million, but Aviragen, formerly Biota Holdings, fell a further 54.5 percent to a market capitalization of $30 million, its lowest valuation since Biotech Daily records began in 2005, when it was worth $339 million. $30 million is a very long way from the all-time high of $546 million on November 30, 2009 and half the previous low of $59 million on October 31, 2008. The closing price of 59.3 US cents is equivalent to 9.7 Australian cents. Biota was trading around $1.00 when the company decided to move to the US to list on the Nasdaq (BD: Nov 19, 2015).
BDI-40 v S&P ASX200 Jun 30, 2006 to Feb 28, 2017 
BDI-40 v S&P ASX200 Feb 29, 2016 to Feb 28, 2017 
Big Caps (Cochlear, CSL, Resmed) Feb 29, 2016 to Feb 28, 2017


 Click here for Biotech Daily's archive



Biotech Daily Top 40 With Market Capitalization At February 28, 2017



* Biotech Daily editor, David Langsam, owns shares in Acrux, Admedus, Benitec, Mesoblast
   Nanosonics, Neuren and Volpara, as well as non-biotechnology stocks.
   Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies. 

   These holdings are liable to change: